Gene therapy developer Asklepios BioPharmaceutical gained $235 million through an investment made by Vida Ventures and TPG Capital, along with one by AskBio's board and founders. The money will be used to fund gene therapy research and development for rare genetic disorders.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.